TANG CAPITAL MANAGEMENT LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001232621

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth Tilt how tags are computed

Q2 2026 · 41 positions · Total reported value $2.20B · Top-10 concentration 62.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 15.2% · 5 new · 1 cut · 1 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.5% · vs SPY -10.6% · Prev Value $2.20B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.0% · vs SPY -5.2% · Latest Value $2.17B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, TANG CAPITAL MANAGEMENT LLC disclosed 41 equity positions with a combined reported value of $2.20B. The filing implies a focused portfolio: its ten largest positions account for 62.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were AUPH ($221.36M), SYRE ($167.99M), MIRM ($144.70M). By sector, the heaviest allocations are Health Care 89.7%, Information Technology 0.9%. Versus the prior quarter, allocation shifted toward Health Care (+6.0pp), Information Technology (+0.9pp) and away from Other (-6.9pp).

Versus the prior quarter, TANG CAPITAL MANAGEMENT LLC opened 5 new positions, trimmed 1 and fully exited 1, a turnover rate of 15.2% of positions. The portfolio's overlap with the prior quarter was 64% of names.

The largest new positions opened in Q2 2026 were NVCT ($28.50M), FULC ($23.87M), NNDM ($20.72M).

Of the 1 positions fully exited versus the prior quarter, the largest were KALV ($92.07M), JANX ($6.95M), BIIB ($6.42M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • NVCT NUVECTIS PHARMA INC · $28.50M
  • FULC FULCRUM THERAPEUTICS INC · $23.87M
  • NNDM NANO DIMENSION LTD · $20.72M
  • GOSS GOSSAMER BIO INC · $11.47M
  • BOLD BOUNDLESS BIO INC · $6.40M

Fully Exited (vs previous quarter)

  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $92.07M
  • JANX JANUX THERAPEUTICS INC · prev qtr: $6.95M
  • BIIB BIOGEN INC · prev qtr: $6.42M
  • URGN UROGEN PHARMA LTD · prev qtr: $6.29M
  • ARVN ARVINAS INC · prev qtr: $5.71M
  • KZR KEZAR LIFE SCIENCES INC · prev qtr: $4.93M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $3.38M
  • ERAS ERASCA INC · prev qtr: $3.24M

Insider Transactions (Form 4)

Latest TANG CAPITAL MANAGEMENT LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Boundless Bio, Inc. 249 $2.40 SEC filing
2026-11-06 Buy Boundless Bio, Inc. 1,700 $2.40 SEC filing
2026-11-05 Buy Boundless Bio, Inc. 8,390 $2.40 SEC filing
2026-11-04 Buy Boundless Bio, Inc. 517 $2.40 SEC filing
2026-11-03 Buy Boundless Bio, Inc. 2,255 $2.40 SEC filing
2026-10-27 Buy Boundless Bio, Inc. 10,707 $2.40 SEC filing
2026-10-26 Buy Boundless Bio, Inc. 9,606 $2.38 SEC filing
2026-10-23 Buy Boundless Bio, Inc. 6,234 $2.38 SEC filing

All insider transactions →

Fund Profile

Tang Capital Management is an SEC-registered 13F filer. As of Q3 2026 it reported 45 US equity positions with a combined value of $2.17B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 45 positions · $2.17B reported value (Q3 2026)
  • Top 10 holdings = 64.3% of reported value
  • Largest position: AUPH (AURINIA PHARMACEUTICALS INC) at 9.7%
  • Average position size: $48.31M

Sector Tilt

  • Health Care 89.7%
  • Information Technology 1.5%
  • (classified holdings cover 91% of value)

Quarterly Activity

  • Q3 2026: 5 new, 12 added, 1 reduced, 1 exited
  • 27 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: TANG CAPITAL MANAGEMENT LLC's rebalancing in Q2 2026 appears to reflect a conservative approach with a focus on Health Care sector, indicating a potential preference for stability and growth in this area. 2. Key Moves: - Added: Celucity Inc (CELC), Capricor Therapeutics Inc (CAPR), and Tarsus Pharmaceuticals Inc (TARS). These additions are significant, with CELC showing a substantial increase in share count and weight. - Reduced: None, but AURINIA PHARMACEUTICALS INC (AUPH) saw a notable increase in share count and weight, suggesting a reevaluation rather than a reduction. 3. Portfolio Structure: - Passive/Active: The portfolio seems to lean towards active management, given the selective additions and the changes in weights. - Sector Bias: Strong bias towards the Health Care sector, with 10 of the top 10 holdings in this sector. - Risk Appetite: Moderate to high risk appetite, as evidenced by the substantial additions in share count to certain positions. 4. Per-Holding One-Liner: - AUPH (Aurinia Pharmaceuticals Inc): Develops and commercializes therapies for rare diseases, particularly in the field of nephrology. - SYRE (Spire Therapeutics Inc): Specializes in the development of gene therapies for neurological disorders. - MIRM (Mirum Pharmaceuticals Inc): Focuses on the development of therapies for orphan genetic disorders. - KNSA (Kiniksa Pharmaceuticals Intl): Engages in the research and development of treatments for inflammatory diseases. - CELC (Celucity Inc): Specializes in the development of cancer therapies, including immuno-oncology drugs. - CORT (Corcept Therapeutics Inc): Develops treatments for endocrine disorders, particularly Cushing's syndrome. - PTCT (PTC Therapeutics Inc): Focuses on the development of treatments for rare genetic disorders. - LKFT (Lakefront Biotherapeutics NV): Specializes in the development of treatments for rare genetic diseases. - CAPR (Capricor Therapeutics Inc): Develops therapies for cardiovascular diseases and genetic disorders. - TARS (Tarsus Pharmaceuticals Inc): Engages in the development of therapies for ophthalmic diseases. 5. One-Sentence Style Summary: TANG CAPITAL MANAGEMENT LLC's Q2 2026 rebalancing emphasizes a strategic focus on the Health Care sector, with active management and a preference for companies with potential for growth and stability in their respective niches.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 89.7%
Other 9.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 13.04M $221.36M 10.05%
10.05%
Add
2 1.89M $167.99M 7.63%
7.63%
Hold
3 1.24M $144.70M 6.57%
6.57%
Hold
4 2.26M $144.52M 6.56%
6.56%
Hold
5 1.31M $137.53M 6.25%
6.25%
Add
6 1.50M $130.43M 5.92%
5.92%
Hold
7 1.50M $122.36M 5.56%
5.56%
Hold
8 3.79M $113.50M 5.16%
5.16%
Hold
9 4.10M $98.73M 4.48%
4.48%
Add
10 1.57M $98.71M 4.48%
4.48%
Add
11 123.00K $91.85M 4.17%
4.17%
Reduce
12 1.33M $89.83M 4.08%
4.08%
Hold
13 2.65M $84.12M 3.82%
3.82%
Hold
14 5.00M $70.75M 3.21%
3.21%
Add
15 707.50K $58.57M 2.66%
2.66%
Hold
16 470.00K $43.73M 1.99%
1.99%
Hold
17 17.99M $39.40M 1.79%
1.79%
Add
18 6.42M $36.58M 1.66%
1.66%
Hold
19 1.79M $32.93M 1.50%
1.50%
Hold
20 1.55M $28.50M 1.29%
1.29%
New
21 264.69K $25.80M 1.17%
1.17%
Hold
22 6.52M $23.87M 1.08%
1.08%
New
23 4.81M $22.39M 1.02%
1.02%
Hold
24 1.16M $20.88M 0.95%
0.95%
Hold
25 14.29M $20.72M 0.94%
0.94%
New
26 500.00K $19.50M 0.89%
0.89%
Hold
27 3.30M $18.74M 0.85%
0.85%
Add
28 450.00K $16.77M 0.76%
0.76%
Hold
29 17.84M $11.47M 0.52%
0.52%
New
30 1.61M $11.40M 0.52%
0.52%
Hold
31 100.00K $10.66M 0.48%
0.48%
Reduce
32 300.00K $9.82M 0.45%
0.45%
Reduce
33 6.14M $7.00M 0.32%
0.32%
Hold
34 2.56M $6.40M 0.29%
Form 4 · 13 →
0.29%
New
35 4.25M $5.69M 0.26%
0.26%
Hold
36 50.00K $3.50M 0.16%
0.16%
Reduce
37 600.00K $3.49M 0.16%
0.16%
Hold
38 6.25M $2.67M 0.12%
0.12%
Hold
39 451.11K $2.56M 0.12%
0.12%
Hold
40 666.02K $2.02M 0.09%
0.09%
Hold
41 100.00K $342.00K 0.02%
0.02%
Hold

FAQ

What did TANG CAPITAL MANAGEMENT LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, TANG CAPITAL MANAGEMENT LLC reported 41 equity positions worth $2.20B in aggregate; its largest disclosed positions were AUPH ($221.36M), SYRE ($167.99M), MIRM ($144.70M).

How large is TANG CAPITAL MANAGEMENT LLC's portfolio?

TANG CAPITAL MANAGEMENT LLC reported $2.20B of long equity holdings across 41 positions as of 2026-Q2. Top-10 holdings account for 62.7% of reported value.

What is TANG CAPITAL MANAGEMENT LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tang-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →